Category: Intellectual property
-
Stem Cell Biotech Licensing Blood Vessel Repair Technology
6 April 2016. Cellular Dynamics International, a developer of regenerative treatments from stem cells, is licensing university research that repairs blood vessels in people with peripheral artery disease. Financial aspects of the deal between Indiana University and Cellular Dynamics, a subsidiary of FujiFilm in Madison, Wisconsin, were not disclosed. Cellular Dynamics designs and generates induced…
-
Regeneron, Bayer Collaborating on Eye Disorder Drug
24 March 2016. Regeneron Pharmaceuticals and drug-maker Bayer AG are developing a combination of biologic drugs to treat the eye disorders wet age-related macular degeneration and diabetic macular edema. The agreement — the third such deal between the companies — is expected to bring Regeneron as much as $130 million if all milestones are met.…
-
New Biotech Begins Work on Enhanced Platinum Cancer Drugs
23 March 2016. A new biotechnology company began work today on developing improved platinum-based treatments for solid tumor cancers. The company, Placon Therapeutics in Cambridge, Massachusetts, is a spin-off enterprise from Tarveda Therapeutics, a developer of biologic cancer drugs. Placon Therapeutics focuses on new treatments for cancer using platinum as a cancer-killing agent that works…
-
Merck Licensing Harvard Cancer Drug Molecules
21 March 2016. The pharmaceutical company Merck is licensing small molecule research discoveries from a Harvard University lab as potential treatments for leukemia. The agreement brings the university $20 million immediately, with further payments expected as Merck develops the discoveries into products. The deal gives Merck an exclusive license to research by biochemistry professor Matthew…
-
Allied-Bristol Licenses NYU Research, Starts New Company
17 March 2016. Allied-Bristol Life Sciences, a joint venture of Allied Minds and Bristol-Myers Squibb, is licensing research from New York University on signaling pathways affecting growth of tumors, for a new company begun under its tutelage. Financial aspects of the deal between Allied-Bristol and NYU were not disclosed. The new enterprise, known as iBeCa…
-
Roche Licensing Biotech Immunotherapies in $1B Deal
15 March 2016. The biotechnology company Blueprint Medicines, a developer of cancer treatments based on a patient’s precise genomic make-up, is partnering with the pharmaceutical company Roche on cancer immunotherapies. The agreement gives Roche options to license up to 5 small-molecule, or low molecular-weight therapies, in a deal that could bring Blueprint more than $1…
-
Genetics Company Makes Available Cancer Sequencing Database
8 March 2016. A genetic testing company is making freely available a database of genomic sequencing data from patients with breast and ovarian cancer. The database, from 10,000 human genomes but with personal identity removed, is offered by Ambry Genetics in Aliso Viejo, California. Ambry Genetics is a 16 year-old company offering genetic tests for…
-
Multiple Myeloma Gene Therapy Trial Underway
19 February 2016. The biotechnology company bluebird bio began testing its experimental gene therapy for multiple myeloma in an early-stage clinical trial. The Cambridge, Massachusetts company — which spells its name in all lower-case letters — is also licensing the technology tested in the trial to the pharmaceutical company Celgene. Multiple myeloma is a cancer of…
-
Biotech Reviewing Stanford Immuno-Stem Cell Technology
16 February 2016. A biotechnology company in Los Angeles is evaluating a technology developed at Stanford University for transferring DNA of immune system cells to a patient’s own stem cells to produce immunotherapies for treating cancer. The agreement with Stanford gives ImmunoCellular Therapeutics Ltd. an option to license the technology from the lab of immunologist…
-
Start-Up Licensing Wayne State Neurological Discoveries
8 February 2016. Wayne State University is licensing research discoveries from its pharmacy school to a new enterprise for development as drugs to treat depression, post-traumatic stress disorder or PTSD, and other neurological disorders. Financial aspects of the agreement with Trimaran Pharma Inc. were not disclosed. The deal covers research by pharmaceutical sciences professor Aloke…